CD8A and neoplasm: Interestingly, DT administration increased the frequency of p15E-specific CD8+ T cells but had a negligible impact on LCMV GP33–41–specific CD8+ T cells (Figure 6, E and F), suggesting that Tregs selectively inhibit the magnitude of endogenous CD8+ T cell responses to facilitate tumor relapse.